CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients (VIEWER)
Chronic Kidney Disease Stage 5, End Stage Renal Disease
About this trial
This is an interventional supportive care trial for Chronic Kidney Disease Stage 5 focused on measuring telemonitoring, chronic kidney disease, suboptimal dialysis initiation, digital health
Eligibility Criteria
Inclusion Criteria: >18 years of age Patient or primary caregiver can read and speak English Patient or patients substitute decision maker is able to provide informed consent Patient or primary care giver cognitively and physically capable and willing to use the VIEWER mobile application and perform self-measurements (i.e. weight, BP, etc.) Have stage 5 CKD (2 measurements of eGFR <15ml/min/1.73m2); eGFR will be calculated with the CKD-EPI equation. Followed in a multidisciplinary CKD clinic Have >40% chance of beginning dialysis in the next 2 years based on the Kidney Failure Risk Equation Exclusion Criteria: Inability of self or caregiver assisted self-monitoring using VIEWER
Sites / Locations
- Chronic Disease Innovation Centre, Seven Oaks HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Intervention Group
Control Group
Participants randomized to the intervention group will be provided with a wireless BP cuff, weight scale, transcutaneous O2 sat monitor, wearable motion tracker and mobile tablet with the VIEWER application. Patients will be trained to use the VIEWER platform either virtually or in person. Patients will be guided through a daily self-assessment routine via the app (BP, weight, O2 saturation, step count upload) and weekly ESAS-r survey. Participants will use the VIEWER platform for 12 months in addition to receiving usual care. Additionally, participants will complete the UK Kidney PREM score (adapted to CKD) and the Health related QOL using KDQOL-SF via REDCap or paper form at baseline, 3, 6, 9 and 12 months, and the System Usability Scale (SUS) at 12 months.
Participants randomized to the control group will continue to receive usual care either virtually via telephone or video call or in person depending on COVID-19 restrictions in place. Participants will complete the UK Kidney PREM score (adapted to CKD) and the Health related QOL using KDQOL-SF via REDCap or paper form at baseline, 3, 6, 9 and 12 months.